drugset / Trial / NCT05117710

IMPase in Treatment-resistant Depression

NCT05117710 ↗

RandomizedParallel-groupQuadruple-blindBasic science

Summary

This experimental medicine study will examine the effects of a brief period (seven days) of 'add on' ebselen (SPI-105) treatment in patients with resistant depression to see if ebselen produces changes in emotional responses consistent with a potential clinical antidepressant effect. The investigators will also seek to confirm ebselen's mode of action on IMPase by measuring changes in a brain chemical called inositol, using a magnetic imaging method. Half of the participants will receive ebselen and the other half placebo.

Timeline

Start
2021-04-22
Primary completion
2024-05-31
Completion
2024-05-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ebselen Small molecule 600 mg Oral